沙库巴曲缬沙坦临床研究文献计量学分析  

Clinical Research of Sacubitril-Valsartan:A Bibliometric Analysis

作　　者：李梦媛[1,2] 曹兆流 鲍柏屹 张莉 王义俊[1,2] LI Mengyuan;CAO Zhaoliu;BAO Baiyi;ZHANG Li;WANG Yijun(Department of Pharmacy,The Second Affiliated Hospital of Nanjing Medical University,Nanjing,Jiangsu,China 210011;School of Pharmacy,Nanjing Medical University,Nanjing,Jiangsu,China 211166;Department of Pharmacy,Nanjing Xixia District Hospital,Nanjing,Jiangsu,China 210046)

机构地区：[1]南京医科大学第二附属医院药学部,江苏南京210011 [2]南京医科大学药学院,江苏南京211166 [3]江苏省南京市栖霞区医院药剂科,江苏南京210046

出　　处：《中国药业》2023年第4期27-34,共8页China Pharmaceuticals

基　　金：江苏省药学会—恒瑞医院药学基金[H202005]。

摘　　要：目的分析沙库巴曲缬沙坦临床研究现状与热点。方法检索Web of Science数据库自建库至2021年12月31日的沙库巴曲缬沙坦临床研究相关文献,应用Excel软件和VOSviewer软件进行数据提取及描述性统计分析,涉及相关发文量年度变化趋势,国家及研究机构、高被引文章、文献期刊的分布等,并对出现频次>13次的主要关键词进行聚类分析,生成高频关键词的聚类网络图。结果共纳入644篇文献,其中英文637篇,西班牙文4篇,俄文2篇,德文1篇;最早一篇发表于2010年,2021年发表179篇。自2015年起全球总发文量呈稳步增长趋势,美国、中国/苏格兰(并列)分居前两名。排名前10的高贡献研究机构中除诺华制药外多为美国高等院校和政府机构。ESC Heart Failure是收录论文量最多的期刊(51篇)。发文量最大的作者发文98篇,单篇文献最高被引3023次。分析高被引文献可知,射血分数保留型心衰(HFpEF)、急性失代偿性心力衰竭、PARADIGM-HF及PARAGON-HF研究分析、改善心脏重构等研究方向受到关注。关键词聚类结果显示,相关研究主要聚焦于3个主题。结论目前沙库巴曲缬沙坦临床研究关注点仍集中于心力衰竭领域,而其作用机制、非心力衰竭领域应用、经济学评价等方面可能成为未来研究热点。随着沙库巴曲缬沙坦纳入国家医疗保险目录,以及高血压适应证的扩展,未来我国相关独立研究将获进一步发展。Objective to the clinical research of sacubitril-valsartan was searched from the Web of Science database from its inception to December 31,2021.Excel software and VOSviewer software were used to extract data and conduct descriptive statistical analysis on these data,which involved the annual change trend of publications,the distribution of nation,research institutions,highly-cited articles,journals,etc.Clustrer analysis was conducted on the main keywords with occurrence frequency of more than 13 times to establish the clustering network diagram of high-frequency keywords.Results English,four articles in Spanish,two articles in Russian and one article in German.The first relevant article was published in 2010,and 179 relevant articles were published in 2021.Since 2015,the global total number of relevant articles has shown a steady growth trend,with the United States of America(USA)and China/Kingdom of Scotland(side by side)ranking the top two.In addition to Novartis Pharmaceuticals,most of the top 10 high-contribution research institutions were universities and government agencies in the USA.ESC Heart Failure was the journal with the most publications which published 51 articles.The author with the largest number of articles published 98 articles,and the highest citation frequency of a single article was 3023 times.The analysis of highly-cited articles showed that the research directions of heart failure with preserved ejection fraction(HFpEF),acute decompensated heart failure(ADHF),PARADIGM-HF and PARAGON-HF analysis,and improvement of cardiac remodeling were concerned.The results of keyword clustering showed that relevant researches mainly focused on three themes.ConclusionThe current clinical research of sacubitril-valsartan still focuses on heart failure,and future research may focus on the mechanism of action,application in non-heart failure field,economic evaluation and so on.With the entry of sacubitril-valsartan into the National Medical Insurance Catalogue and the expansion of hypertension indications,the

关 键 词：沙库巴曲缬沙坦 文献计量学 心力衰竭 临床研究 

分 类 号：R972[医药卫生—药品]